Research programme: DNA vaccines - Inovio/National Cancer Institute

Drug Profile

Research programme: DNA vaccines - Inovio/National Cancer Institute

Latest Information Update: 30 Apr 2012

Price : $50

At a glance

  • Originator Genetronics Inc
  • Developer Inovio Pharmaceuticals; National Cancer Institute (USA)
  • Class AIDS vaccines; Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer; HIV infections

Most Recent Events

  • 30 Apr 2012 No development reported - Preclinical for HIV infections in USA (IM)
  • 30 Apr 2012 No development reported - Preclinical for Cancer in USA (IM)
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top